Hybribio

Hybribio (Stock code: 300639.SZ) is the leading supplier of nucleic acid molecular diagnostic products, also the largest HPV diagnosis device manufacture in China, with a complete operation chain, from research and development, production, to sales. In 2017, Hybribio was listed in GEM of Shenzhen Stock Exchange.

We developed our IVD platform based on patented technology – “Flow-through Hybridization”licensed by The University of Hong Kong，and established two major R&D lines – infectious pathogen detection and genetic disease detection. Our products, which have been approved by CFDA and have obtained CE-IVD, WHO licenses, have been extensively used in medical and research laboratories in European and Asian countries. So far, Hybribio’s diagnostic reagents have been exported to over 30 countries.

Taking advantage of the accumulated experience in the past 16 years, shortly after the outbreak of COVID-19, Hybribio has successfully developed COVID-19 nucleic acid detection kit, to assist medical institutions and disease control departments to take timely and effective prevention and control measures, as one of the accredited product and service provider. On March 4th, our detection kit is also CE-certified by the European Union and WHO EUL qualified by WHO.

Company’s Keywords:

hpv, pcr, screening, std, covid19, nucleic acid, ivd, clinical lab, thallasemia